Umpqua Bank Raises Holdings in Johnson & Johnson (NYSE:JNJ)

Umpqua Bank increased its position in shares of Johnson & Johnson (NYSE:JNJ) by 8.9% in the 4th quarter, Holdings Channel reports. The firm owned 20,555 shares of the company’s stock after purchasing an additional 1,688 shares during the period. Johnson & Johnson accounts for approximately 1.0% of Umpqua Bank’s portfolio, making the stock its 23rd largest position. Umpqua Bank’s holdings in Johnson & Johnson were worth $2,975,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in the company. Intellus Advisors LLC purchased a new stake in shares of Johnson & Johnson during the fourth quarter worth approximately $586,000. Sei Investments Co. grew its holdings in Johnson & Johnson by 6.0% in the 4th quarter. Sei Investments Co. now owns 1,210,211 shares of the company’s stock valued at $175,021,000 after buying an additional 67,981 shares in the last quarter. American Century Companies Inc. grew its holdings in Johnson & Johnson by 4.0% in the 4th quarter. American Century Companies Inc. now owns 7,518,301 shares of the company’s stock valued at $1,087,297,000 after buying an additional 286,239 shares in the last quarter. Plancorp LLC grew its holdings in Johnson & Johnson by 2.6% in the 4th quarter. Plancorp LLC now owns 15,170 shares of the company’s stock valued at $2,194,000 after buying an additional 387 shares in the last quarter. Finally, Runnymede Capital Advisors Inc. purchased a new stake in Johnson & Johnson in the 4th quarter valued at $38,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Trading Up 0.2 %

JNJ opened at $163.40 on Friday. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99. The company has a market cap of $393.76 billion, a P/E ratio of 24.57, a PEG ratio of 2.56 and a beta of 0.47. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. The business’s 50-day simple moving average is $156.99 and its 200-day simple moving average is $156.33.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. The business had revenue of $22.52 billion for the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The business’s revenue for the quarter was up 5.3% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.29 EPS. As a group, equities research analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th were paid a dividend of $1.24 per share. The ex-dividend date was Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a yield of 3.04%. Johnson & Johnson’s dividend payout ratio is presently 74.59%.

Analysts Set New Price Targets

Several brokerages have issued reports on JNJ. Wells Fargo & Company dropped their target price on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a report on Thursday, January 23rd. Guggenheim restated a “neutral” rating on shares of Johnson & Johnson in a report on Monday, March 10th. Raymond James decreased their price target on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating on the stock in a research note on Thursday, January 23rd. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $181.00 price target on shares of Johnson & Johnson in a research note on Wednesday, February 19th. Finally, Argus raised Johnson & Johnson to a “strong-buy” rating in a research note on Friday, January 24th. Nine analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $171.33.

Insider Buying and Selling

In related news, VP Robert J. Decker sold 6,999 shares of the firm’s stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the transaction, the vice president now owns 21,001 shares in the company, valued at $3,483,645.88. This trade represents a 25.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Timothy Schmid sold 403 shares of the stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the sale, the executive vice president now directly owns 15,098 shares of the company’s stock, valued at $2,357,552.70. The trade was a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.